ELYS promotes hepatocellular carcinoma stemness by activating a FOXO6-NUP205 transcriptional module downstream of PI3K/AKT to drive Hedgehog signaling Authors: Xin Chen, Qing Zhang, Fen Xie, Huilan Zhai, Chuanhong Li, Weifeng Zhou, Nuobei Zhang Published: 2026 ABSTRACT BackgroundHepatocellular carcinoma (HCC) is a lethal malignancy driven by cancer stem cells, which drive progression and therapeutic resistance. Nuclear pore protein ELYS is implicated in tumorigenesis, but its role in HCC stemness remains unclear.MethodsTranscriptome sequencing identified ELYS-induced differentially expressed genes (DEGs). Functional impacts of ELYS on malignant phenotypes and stemness were assessed in vitro. Signaling pathway activation was confirmed using inhibitors of Hedgehog (GANT-61) and AKT (MK-2206 2HCl). Bioinformatics analysis, luciferase reporter, and ChIP assays elucidated the FOXO6-NUP205 axis. Xenograft models validated the findings in vivo. Clinical relevance was evaluated using TCGA-HCC data and immunohistochemistry in clinical samples.ResultsDEGs in ELYS-overexpressing cells were enriched in PI3K/AKT and Hedgehog (Hh) pathways. ELYS facilitated Gli-1 nuclear translocation by activating PI3K/AKT, placing it upstream of Hh. Bioinformatic and experimental analyses identified FOXO6 and its target NUP205 as key effectors. ELYS upregulated FOXO6, which directly activated NUP205 transcription. FOXO6 knockdown suppressed ELYS-induced effects on NUP205, Gli-1 nuclear translocation, and stemness factors. In vivo, ELYS promoted tumor growth and lung metastasis via PI3K/AKT/Hh. Clinically, ELYS, FOXO6, and NUP205 were overexpressed in HCC, correlating with advanced features and poor survival.ConclusionThis study defines an oncogenic axis wherein ELYS promotes HCC stemness and metastasis by activating PI3K/AKT, triggering a FOXO6-NUP205 cascade to drive Hedgehog, representing a pivotal mechanism and therapeutic target.Graphical abstract Introduction Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer, accounting for over 90% of primary liver cancers [1]. It is a highly malignant tumor characterized by a high rate of recurrence and metastasis, and the prognosis of HCC varies depending on individual factors [2]. Patients with localized tumors generally have a better prognosis, with early detection and treatment resulting in a significant improvement in cure rates and survival [3]. Conversely, patients with advanced disease and metastasis tend to have a poorer prognosis [4]. Despite the strides made in treatment approaches in recent years, HCC persists as a significant health challenge due to its high incidence, recurrence, and mortality rates [5]. Growing attention has been paid to the association between stem cell properties and the progression of HCC [6]. The aberrant activation of stem cell-like features in tumor cells is regarded as a pivotal driver of tumor initiation and progression [7]. Studies have shown that certain HCC cells exhibit stemness characteristics, which play crucial roles in the initiation, progression, metastasis, therapeutic resistance, and post-treatment recurrence of HCC [8]. Therefore, a full understanding of the mechanisms underlying the acquisition and maintenance of stem cell properties in HCC cells is imperative for the development of more effective therapeutic strategies. Multiple stem cell-related signaling pathways play crucial roles in HCC, not only in normal liver development but also in the occurrence and progression of HCC [9, 10]. Among these pathways, the Hedgehog (Hh) signaling pathway is a pivotal developmental signaling cascade that governs cell proliferation, differentiation, and survival by modulating gene expression [11]. The activation of this pathway occurs primarily through the ligands Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH) [12]. These ligands bind to the receptor Patched (PTCH), relieving the inhibitory effect on Smoothened (SMO), thereby activating downstream transcription factors Gli (Glioma-associated oncogene) [13]. The translocation of Gli transcription factors to the nucleus is a crucial step in this process, wherein they modulate the expression of genes implicated in cell proliferation, differentiation, migration, and self-renewal [14]. Notably, studies have shown that stem cells in HCC frequently exhibit aberrant activation of the Hh pathway, which is associated with enhanced stem cell proliferation, self-renewal capacity, and drug resistance [15]. Consequently, an in-depth investigation into the relationship between the Hh signaling pathway and stem cell features in HCC is warranted. The AT-hook containing transcription factor 1 (AHCTF1), also known as ELYS, is an indispensable multi-domain nucleoporin (NUP) and a pivotal component of the nuclear pore complex (NPC) Nup107-160 subcomplex [16, 17]. ELYS is crucial for nuclear pore assembly and mitosis, and plays a key role in diverse cellular events, including cell proliferation and cell cycle regulation [18]. Owing to its unique functions, ELYS has attracted increasing attention. A growing number of studies have indicated the association between ELYS and various types of cancer, including colorectal cancer [19], thyroid cancer [20], and HCC [21, 22]. Our preliminary data further support its relevance in HCC, showing that ELYS overexpression enhances fatty acid oxidation (FAO) in oxaliplatin-treated HCC cells, which suggests a potential role in promoting metabolic adaptation and chemoresistance. Nevertheless, research on the specific role of ELYS in HCC remains limited. This study aims to initially reveal the complex relationship between ELYS and the Hh signaling pathway, as well as HCC stem cell features, and to provide a theoretical basis and new insights for the development of more effective therapeutic strategies for HCC. Materials and methods Bioinformatics Differentially expressed genes (DEGs) between control and ELYS-overexpressing Huh7 cells were identified through transcriptome sequencing. The “DESeq2” package in R was utilized to filter DEGs based on the criteria of adjusted p-value (padj) < 0.05 and abs(log2FC) > 0.5. The Benjamini–Hochberg method was applied for multiple-testing correction. These genes were visualized using the “ggplot2” package to generate a volcano plot, while a heatmap highlighting DEGs between the two groups was created with the “pheatmap” package. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the identified DEGs were conducted with the “clusterProfiler” package in R. RNA-sequencing data and corresponding clinical data for HCC were obtained from The Cancer Genome Atlas (TCGA). Tumor samples were dichotomized into ELYS-high and ELYS-low groups based on the median expression level of ELYS (n = 166 per group). Differential expression analysis between these groups was conducted using the R package “DESeq2” (v.1.48.1). DEGs were defined with a threshold of adjusted p-value (padj) < 0.05 and abs(log2FC) > 0.5, with the Benjamini–Hochberg method applied for multiple-testing correction. The results were visualized in a volcano plot using the “ggplot2” package (v.3.5.1). Transcription factors putatively targeting the NUP205 promoter and genes associated with the PI3K/AKT signaling pathway were retrieved from the JASPAR database (version 2024) and the MSigDB database, respectively. The intersection among these Transcription factors, PI3K/AKT pathway genes, and the upregulated DEGs from the ELYS-high group was determined by a Venn diagram. A stemness-related gene signature, “MALTA_CURATED_STEMNESS_MARKERS” (MSigDB ID: M30411, version v2025.1.Hs), was obtained from the Molecular Signatures Database (MSigDB). Single-sample Gene Set Enrichment Analysis (ssGSEA) was performed using the “GSVA” package (v.1.50.5) to calculate a stemness score for each tumor sample in the TCGA cohort. Samples were stratified into high and low expression groups based on the median expression of FOXO6 and PITX2, respectively. Differences in stemness scores between these groups were assessed using the Wilcoxon test from the “ggpubr” package (v.0.6.1) and visualized via violin plots created with “ggplot2”. Human hepatocellular carcinoma bulk RNA-seq data and corresponding clinical survival data were downloaded from the TCGA database, including 50 adjacent normal samples and 365 tumor samples with complete survival information. Differential expression analysis between Tumor and Normal groups was performed using the R package DESeq2 (v.1.50.2), with differentially expressed genes (DEGs) identified using the criteria padj < 0.05 and |log2FoldChange| > 0.5. Volcano plots, bar plots, and heatmaps of DEGs were generated using the R packages ggplot2 (v.4.0.2) and ComplexHeatmap (v.2.26.1). The FPKM expression levels of ELYS, FOXO6, and NUP205 were extracted from the bulk RNA-seq data, and violin-boxplots were generated using ggplot2 (v.3.5.1) to visualize their expression distribution between tumor and normal samples, with padj values annotated. For survival analysis, optimal cut-off values for each gene were determined using the surv_cutpoint function from the survminer package (v.0.5.2) with minprop = 0.1, and Kaplan-Meier survival curves were generated using the survival (v.3.8.6) and survminer (v.0.5.2) packages, with statistical significance assessed by the log-rank test. For clinical correlation analysis (Table 4), HCC tumor samples were divided into high- and low-expression groups based on the median expression level of each gene. Clinical characteristics were categorized as follows: age (≤ 60 vs. >60 years), sex (Female vs. Male), overall Stage (I/II vs. III/IV), T stage (T1, T2, T3/4), N stage (N0 vs. N1), and M stage (M0 vs. M1). The Chi-square test was performed using the CreateTableOne function from the tableone package (v.0.13.2) to compare clinical characteristics between high- and low-expression groups. Cells The human hepatocellular carcinoma cell lines utilized in this study were Huh7 (YDT-0003) and HepG2 (YDT-0235). All cell lines were sourced from INDIT Bio-Technology Co., Ltd (Hangzhou, China). Huh7 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, BDBIO, Hangzhou, China, L100-500). HepG2 cells were cultured in Minimum Essential Medium (MEM, BDBIO, Hangzhou, China, L105-500). Both media were supplemented with 10% fetal bovine serum (FBS, SERANA, Shanghai, China, s-FBS-x-015) and 1% penicillin/streptomycin (Gibco, CA, USA, 15140-122). The cells were incubated at 37 °C in a 5% CO2 atmosphere. Cell transfection To establish Huh7 and HepG2 cell lines overexpressing ELYS, the human ELYS CDS sequence (NM_015446) was synthesized and inserted into the pcDNA3.1 vector (Youbao, China, VT1001). Once the cells had reached 80% confluence, they were transfected with recombinant plasmids or empty plasmids using Lipofectamine 2000 (Invitrogen, USA, 11668-019) for 24 h. The ELYS-overexpressing lentivirus (Lenti-ELYS) and its corresponding control (Lenti-control) were obtained from Aikangde (Suzhou, China). Huh7 cells were infected with the aforementioned lentivirus (MOI = 200) for 24 h. Subsequently, cells were selected with 1 µg/mL puromycin (A1113802, Thermofisher, Boston, USA) selection. The efficiency of transfection was verified by Western blotting. All siRNA constructs obtained from Hippo Bio (Huzhou, China) were transfected into 70–80% confluent cells in 6-well plates. The transfection complex was prepared by mixing 2 µL siRNA (100 nM final concentration) and 2 µL Lipofectamine 2000 in Opti-MEM I Reduced Serum Medium (Gibco, 31985-070) for transfection. The siRNA sequences are listed in Table 1. Table 1The sequences of siRNAsNameSequencesiR-NC senseUUCUCCGAACGAGUCACGUTTsiR-NC antisenseACGUGACUCGUUCGGAGAATTsiR-FOXO6-1 senseGCGACGAAAUGGACUUCAACUsiR-FOXO6-1 antisenseUUGAAGUCCAUUUCGUCGCUGsiR-FOXO6-2 senseGGGCCGUGUCCAUGGACAACGsiR-FOXO6-2 antisenseUUGUCCAUGGACACGGCCCUGsiR-FOXO6-3 senseGGCAAGAGUUCGUGGUGGAUGsiR-FOXO6-3 antisenseUCCACCACGAACUCUUGCCGG Table 1The sequences of siRNAsNameSequencesiR-NC senseUUCUCCGAACGAGUCACGUTTsiR-NC antisenseACGUGACUCGUUCGGAGAATTsiR-FOXO6-1 senseGCGACGAAAUGGACUUCAACUsiR-FOXO6-1 antisenseUUGAAGUCCAUUUCGUCGCUGsiR-FOXO6-2 senseGGGCCGUGUCCAUGGACAACGsiR-FOXO6-2 antisenseUUGUCCAUGGACACGGCCCUGsiR-FOXO6-3 senseGGCAAGAGUUCGUGGUGGAUGsiR-FOXO6-3 antisenseUCCACCACGAACUCUUGCCGG The sequences of siRNAs Western blotting (WB) Cell lysates were collected for protein extraction. Protein concentrations were determined using a BCA assay kit (Beyotime, Shanghai, China, P0012). The detailed steps of WB assays were performed in accordance with the published description [23]. The chemiluminescent substrate kit (Thermo Fisher, USA, 32209) was employed to visualize the protein bands. β-actin served as the loading control. The specific details of the antibodies used are presented in Table 2. Table 2Details of antibodiesNameBrandNumberp-PI3KCST17366TPI3KSanta Cruzsc-1637p-AKTCST4060 SAKTproteintech60203-2-lgp-ERKproteintech28733-1-APERKproteintech51068-1-APSHHCST2287PTCH1abcamab51983SMOabcamab235183SUFUabcamab28083Gli-1proteintech66905-1-IGLamin-B1abcamab16048SOX2proteintech66411-1-IgOCT4proteintech11263-1-APNanogCST4903TELYSproteintech30923-1-APELYS (IHC)ThermoFisherPA5-148386Ki67 (IHC)proteintech28074-1-APβ-actinabclonalAC026FOXO6proteintech67201-1-IgNUP205proteintech24439-1-AP Table 2Details of antibodiesNameBrandNumberp-PI3KCST17366TPI3KSanta Cruzsc-1637p-AKTCST4060 SAKTproteintech60203-2-lgp-ERKproteintech28733-1-APERKproteintech51068-1-APSHHCST2287PTCH1abcamab51983SMOabcamab235183SUFUabcamab28083Gli-1proteintech66905-1-IGLamin-B1abcamab16048SOX2proteintech66411-1-IgOCT4proteintech11263-1-APNanogCST4903TELYSproteintech30923-1-APELYS (IHC)ThermoFisherPA5-148386Ki67 (IHC)proteintech28074-1-APβ-actinabclonalAC026FOXO6proteintech67201-1-IgNUP205proteintech24439-1-AP Details of antibodies Nuclear-cytoplasmic separation experiment Nuclear-cytoplasmic fractionation was performed using the Nucleoprotein and Cytoplasmic Protein Extraction Kit (Beyotime, China, P0027). Cells were collected and centrifuged to obtain a cell pellet. Phenylmethylsulfonyl Fluoride (PMSF) was subsequently added to the protein extraction reagent, achieving a final concentration of 1 mM. A volume of 200 µL of the PMSF-supplemented Cytoplasmic Protein Extraction Reagent A was added for every 20 µL of cell precipitate. The mixture was vigorously vortexed for 5 s to ensure complete resuspension and dispersion of the cell precipitate. Subsequently, the samples were placed on ice for 15 min. 10 µL of Cytoplasmic Protein Extraction Reagent B was added, followed by a 5 s vortex at maximum speed and a 1 min incubation on ice. The sample was then centrifuged at 12,000× g for 5 min at 4 °C. The supernatant was carefully transferred into a pre-chilled plastic tube, which was the cytoplasmic protein obtained from the extraction. For precipitation, any residual supernatant was entirely aspirated, and PMSF-supplemented Nuclear Protein Extraction Reagent was subsequently added. The sample was placed on ice and vortexed every 2 min for 30 s over 30 min. It was then centrifuged at 12,000× g for 10 min at 4 °C. The supernatant was carefully transferred into a pre-chilled plastic tube, which was the nuclear protein obtained from the extraction. The subsequent steps were carried out in accordance with the WB protocol. Immunofluorescence (IF) assay Cells were seeded into glass-bottom culture dishes. After the cells were adhered to the surface, they were fixed with 4% paraformaldehyde for 20 min. Subsequently, the cells were washed with PBS and blocked with 5% BSA for 2 h. The primary antibody was diluted in accordance with the instructions and incubated with the cells overnight at 4 °C. After removing the unbound primary antibody, the cells were incubated with a fluorescence-conjugated secondary antibody at room temperature for 1 h. The cell nuclei were stained with DAPI (Roche, NJ, USA, 10236276001) for 10 min. Fluorescent signals were visualized and imaged using a fluorescence microscope. Wound healing assay The bottom of a 6-well plate was evenly marked with horizontal lines. The cells were then seeded into the wells. After the cells adhered to the wall, they were treated according to the experimental requirements. Subsequently, scratches perpendicular to the aforementioned horizontal lines were created in the 6-well plate with a 10 µL pipette tip. After washing the cells, 1 mL of serum-free medium was added to each well and the cells were photographed (0 h). The plates were incubated at 37 °C in a humidified incubator, and additional images were taken at subsequent time points (24, 48, 72 h) using the same field of view. Sphere formation assay The cells were seeded into low-adhesion plates at a density of 3 × 103 cells per well. The spheroid culture medium consisted of fibroblast growth factor (FGF, 10 ng/mL, Aladdin, Shanghai, China, rp155946), epidermal growth factor (EGF, 20 ng/mL, Aladdin, Shanghai, China, rp145392), B27 supplement (Thermo, 1% v/v, MA, USA, MHCIFG29), and insulin (MCE, 16 µg/mL, NJ, USA, hyy-p73243). Following a 10-day incubation period, the formation of cell spheroids was observed under a microscope and images were captured. Flow cytometry Following the collection and washing with PBS, HCC cells were incubated with a CD90 fluorescent antibody (Thermo Fisher, MA, USA, 12-0909-42) for 30 min under light-free conditions. The level of CD90 in the HCC cells was then assessed using a flow cytometer (Thermo Fisher, MA, USA, A24858). Transwell assay In the migration experiments, Huh7 cells were seeded in each upper chamber (Millipore, USA, CLS3396) in a serum-free environment, while the lower chamber was filled with medium enriched with 10% FBS. Following a 48 h incubation, the cells underwent fixation using methanol and were subsequently stained with crystal violet. The stain was removed with PBS and the chambers were left to dry. Invasion experiments were conducted through the addition of Matrigel (Corning, USA, 354234) to the upper chamber 30 min in advance. To capture and document the process of cellular migration and invasion, observations were made and images were captured utilizing a microscope (Olympus Corp, China, IX73). Colony formation assay The 6-well plates were inoculated with HCC cells (1 × 103 cells/well). The cells were subsequently incubated in standard conditions (5% CO2, 37 °C) for 10 days, and the medium was refreshed every 3 days during the culturing process. Upon completion of the culture period, the cells underwent fixation with methanol (Aladdin, Shanghai, China, M116118) for a period of 20 min, followed by two PBS washes. Subsequently, colonies were stained with 0.5% crystal violet (Aladdin, Shanghai, China, C110703) for 30 min. The dye remnants were eliminated through washing with PBS, after which the 6-well plates were left to air-dry. Photographs of the cell colonies were taken and their numbers were counted. Methylthiazolyl diphenyltetrazolium bromide (MTT) assay HCC cells were seeded into 96-well plates, with each well receiving 3000 cells in number. Following incubation periods of 24 h, 48 h, and 72 h, respectively, 50 µL of MTT solution (Sigma, MO, USA, M2128) was dispensed into each well of the 96-well plate. Subsequently, the cells were incubated for 3 h in the dark. Following incubation, 150 µL of a dimethyl sulfoxide (DMSO) solution (HUSHI, Shanghai, China, 30072418) was added to each well. The microplate reader (Thermo Fisher, MA, USA, 51119570) was used to measure the absorbance value at 570 nm. Construction of animal models in vivo Female nude mice, obtained from Vital River Laboratory Animal Technology Co., Ltd (Jiaxing, China), were housed in a controlled specific-pathogen-free environment with a 12 h light/12 h dark cycle and a temperature maintained at 22℃ for approximately one week. The mice were assigned to three groups: Lenti-control, Lenti-ELYS, and Lenti-ELYS + MK-2206 2HCl. Xenograft tumor models were established by subcutaneously injecting Huh7 cells with stable overexpression of ELYS or control cells (4 × 106 cells per mouse) into 5-week-old female nude mice (n = 6). Treatment group mice were orally gavaged with 100 µL of MK-2206 2HCl (120 mg/kg), while mice in the other two groups were given equal amounts of saline. Tumor growth was closely monitored, and once the control group tumors reached a volume of 1500 mm³, all mice were euthanized. Tumors were excised, and their volumes and weights were measured. In the lung tumor metastasis models, the mice were inoculated with Huh7 cells stably transfected with ELYS-overexpressing plasmids or pcDNA3.1 plasmids via tail vein injection (4 × 106/200 µL). The grouping and treatment methods were consistent with the xenograft tumor models. Three weeks later, the nude mice were euthanized. Lung tissues were isolated from the mice, and the number of metastatic foci was recorded. The animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023) and the Guiding Principles in the Care and Use of Animals (China), and were approved by The Laboratory of Animal Experimental Ethical Inspection of Dr. Can Biotechnology (Zhejiang) Co., Ltd (No. DRK20240903). Hematoxylin-eosin (HE) staining Tumor tissues and lung metastatic foci were preserved in 10% neutral formalin, subsequently rinsed with PBS, and then dehydrated through a series of graded ethanol solutions. The paraffin-embedded samples were processed into thin sections, from which the wax was extracted using xylene. These sections were then subjected to a rehydration process involving a graded series of alcohol solutions. Following rehydration, the tissue sections were stained with hematoxylin and eosin (H&E, Solarbio, G1120). After staining, the sections were once again dehydrated and cleared of remaining solvents using xylene. Finally, they were mounted onto slides using neutral balsam for microscopic examination. Immunohistochemical (IHC) IHC staining was conducted to evaluate the expression of the target protein within tumor tissues. Samples were fixed in 4% paraformaldehyde for one week, and dehydrated through a series of ethanol and xylene solutions before being embedded in paraffin. Five-micrometer-thick tissue sections were first deparaffinized, rehydrated, and subjected to antigen retrieval. After an overnight incubation with primary antibodies, secondary antibodies were applied, and the samples were subjected to DAB staining (Beyotime, China, P0202). The antibodies used in this experiment are presented in Table 2. The results were subsequently observed under a microscope. Dual-luciferase reporter assay The promoter fragment of NUP205 containing the predicted wild-type FOXO6 binding site was cloned into the pGL3-Basic vector (Promega) to generate the NUP205-WT reporter plasmid. Site-directed mutagenesis was then performed to create the mutant reporter plasmid (NUP205-Mut). For the luciferase assay, Huh7 cells were co-transfected with one of the reporter plasmids (NUP205-WT, NUP205-Mut, or empty pGL3 vector) and either an ELYS overexpression plasmid (pcDNA3.1-ELYS) or the corresponding empty vector control (pcDNA3.1). Cells were lysed 24 h after transfection, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla activity. All experiments were performed in biological triplicates. Chromatin immunoprecipitation (ChIP) ChIP assay was conducted to verify FOXO6 binding to the NUP205 promoter. Huh7 cells were crosslinked (1% formaldehyde, 37 °C, 10 min), lysed, and chromatin was sheared to 200–1000 bp. After centrifugation, 40 µL of the diluted lysate was reserved as the Input control. The remaining lysate was immunoprecipitated with anti-FOXO6 antibodies (4 °C overnight) followed by Protein A/G bead capture. Complexes were washed, eluted, and crosslinks were reversed by incubation with 5 M NaCl at 65 °C for 4 h. DNA was purified and analyzed by qPCR targeting specific NUP205 promoter regions, with enrichment calculated relative to the IgG control (using the ΔΔCt method, normalized to input DNA). All experiments were performed in triplicate to ensure reproducibility. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) The mRNA expression level of NUP205 in Huh7 cells was quantified by quantitative reverse transcription PCR (qRT-PCR). Total RNA was extracted using TRIzol reagent (Ambion, USA, 15596018). Subsequently, cDNA was synthesized from 1 µg of total RNA using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, K1622). qPCR amplification was performed with SYBR Green Pro Taq HS Premix (ACCURATE, AG11718) on a StepOnePlus Real-Time PCR System (Applied Biosystems). Melting curve analysis was performed after amplification to verify the specificity of the PCR products. The relative expression of NUP205 was normalized to β-actin and calculated using the 2(–ΔΔCt) method. The primer sequences used are listed in Table 3. Table 3The list of primersPrimerForward (5’-3’)Reverse (5’-3’)β-actinCATGTACGTTGCTATCCAGGCCTCCTTAATGTCACGCACGATNUP205GTCATAAATGGGCGTCATAGAATCTGCTCTGGGTCAPTCH1CGCTCTGGAGCAGATTTCCACCACAACCAAGAACTTGCCGGli-1CTGAGCCTTATGGAGCGAGGTTCAAGTCGAGGACACTGGC Table 3The list of primersPrimerForward (5’-3’)Reverse (5’-3’)β-actinCATGTACGTTGCTATCCAGGCCTCCTTAATGTCACGCACGATNUP205GTCATAAATGGGCGTCATAGAATCTGCTCTGGGTCAPTCH1CGCTCTGGAGCAGATTTCCACCACAACCAAGAACTTGCCGGli-1CTGAGCCTTATGGAGCGAGGTTCAAGTCGAGGACACTGGC The list of primers Statistical analysis GraphPad Prism 6.0 (USA, SCR_002798) was used to analyze differences between the two groups using a t-test, and comparisons among multiple groups were evaluated through one-way ANOVA. Data were derived from at least three independent experiments and are presented as mean ± standard deviation (SD). The statistical significance level was set at 0.05; * corresponds to a p-value < 0.05; ** corresponds to a p-value < 0.01. Figures were created using Photoshop CC 2019 (Adobe, USA). Results The DEGs induced by ELYS were potentially associated with the PI3K/AKT and Hh signaling pathways ELYS has been implicated in tumor progression through various signaling pathways, with elevated ELYS expression closely linked to enhanced tumor proliferation and metastasis [21, 22]. To evaluate the impact of ELYS in HCC, DEGs in control and ELYS-overexpressing Huh7 cells were identified through transcriptome sequencing analysis. The DEGs were filtered using the “DESeq2” package in R, and the volcano plot revealed 1030 upregulated genes and 814 downregulated genes in ELYS-overexpressing Huh7 cells compared to the control group (Fig. 1A). These significant DEGs were visualized in a heatmap (Fig. 1B). GO and KEGG enrichment analyses indicated that the DEGs were mainly enriched in the Hh and PI3K/AKT signaling pathways (Fig. 1C & D). Fig. 1The DEGs induced by ELYS were potentially associated with the PI3K/AKT and Hh signaling pathways. The transcriptome sequencing analysis was conducted to identify DEGs in Huh7 cells with control or ELYS overexpression (n = 3). A The R package generated a volcano plot and showed the distribution of DEGs, with the X-axis representing the log2 of the fold change and the Y-axis representing the P value (-log10). B A heatmap was utilized to visualize the significant DEGs. (C&D) The biological processes and pathways in which DEGs were enriched were identified by GO C and KEGG D enrichment analysis The DEGs induced by ELYS were potentially associated with the PI3K/AKT and Hh signaling pathways. The transcriptome sequencing analysis was conducted to identify DEGs in Huh7 cells with control or ELYS overexpression (n = 3). A The R package generated a volcano plot and showed the distribution of DEGs, with the X-axis representing the log2 of the fold change and the Y-axis representing the P value (-log10). B A heatmap was utilized to visualize the significant DEGs. (C&D) The biological processes and pathways in which DEGs were enriched were identified by GO C and KEGG D enrichment analysis ELYS activated the PI3K/AKT and Hh signaling pathways and promoted cell stemness in HCC cells To further explore the mechanism of ELYS in HCC, Huh7 and HepG2 cells were transfected to overexpress ELYS, and the indexes related to the PI3K/AKT and Hh signaling pathways were subsequently examined. The results demonstrated that overexpression of ELYS upregulated the expression levels of key proteins in the PI3K/AKT and Hh pathways, including p-PI3K (Phosphorylated Phosphatidylinositol 3-kinase), p-AKT (Phosphorylated Protein Kinase B), p-ERK (Phosphorylated Extracellular Signal-Regulated Kinase), and Gli-1 (Glioma-associated oncogene), while simultaneously decreasing the expression level of SUFU (Suppressor of Fused), the inhibitory molecule of the Hh pathway (Fig. 2A&B). This suggested that overexpression of ELYS promoted the activity of PI3K/AKT and Hh signaling pathways. Gli-1 is a key transcription factor in the Hh signaling pathway. The increased nuclear expression of Gli-1 is implicated in the regulation of malignant behaviors, such as proliferation, migration, and invasion in HCC cells [24]. To further elucidate the regulatory role of ELYS on Gli-1, we conducted nuclear-cytoplasmic separation experiments and IF assays to assess the distribution of Gli-1 in both the cytoplasm and nucleus, which was associated with tumor cell proliferation and survival. The results demonstrated that overexpression of ELYS resulted in a significant increase in the level of Gli-1 in the nucleus and a relative decrease in the expression level in the cytoplasm (Fig. 2C&D). This finding suggested that ELYS exerted a facilitating effect on the nuclear translocation of Gli-1, thereby activating the Hh signaling pathway. To determine whether the nuclear-accumulated Gli-1 was functionally active, we measured the mRNA levels of canonical Gli-1 target genes by qRT-PCR. As shown in Fig. 2E, ELYS overexpression significantly upregulated the expression of PTCH1 and Gli-1 in both Huh7 and HepG2 cells, confirming that ELYS enhances the transcriptional activity of Gli-1. Furthermore, the results from wound healing assays confirmed that overexpression of ELYS significantly enhanced HCC cell migration (Fig. 3A). Fig. 2ELYS activated the Hh and PI3K/AKT signaling pathways in HCC cells. Huh7 and HepG2 cells were transfected with ELYS-overexpressing or empty plasmids (pcDNA3.1). A WB assays were used to detect the effect of ELYS overexpression on the expression levels of PI3K/AKT pathway-related proteins, including p-PI3K, PI3K, p-AKT, AKT, p-ERK, and ERK in Huh7 and HepG2 cells. B WB assays were used to detect the effect of ELYS overexpression on the expression levels of Hh pathway-related proteins, including SHH, PTCH1, SMO, SUFU, and Gli-1 in Huh7 and HepG2 cells. C A nuclear-cytoplasmic separation kit was used to detect the expression level of Gli-1 protein in the cytoplasm and nucleus of Huh7 and HepG2 cells overexpressing ELYS. D Immunofluorescence staining was used to detect the expression level of Gli-1 in the cytoplasm and nucleus of Huh7 and HepG2 cells overexpressing ELYS. E qRT-PCR was performed to measure the mRNA levels of canonical Gli-1 target genes (PTCH1 and Gli-1) in Huh7 and HepG2 cells with or without ELYS overexpression. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS activated the Hh and PI3K/AKT signaling pathways in HCC cells. Huh7 and HepG2 cells were transfected with ELYS-overexpressing or empty plasmids (pcDNA3.1). A WB assays were used to detect the effect of ELYS overexpression on the expression levels of PI3K/AKT pathway-related proteins, including p-PI3K, PI3K, p-AKT, AKT, p-ERK, and ERK in Huh7 and HepG2 cells. B WB assays were used to detect the effect of ELYS overexpression on the expression levels of Hh pathway-related proteins, including SHH, PTCH1, SMO, SUFU, and Gli-1 in Huh7 and HepG2 cells. C A nuclear-cytoplasmic separation kit was used to detect the expression level of Gli-1 protein in the cytoplasm and nucleus of Huh7 and HepG2 cells overexpressing ELYS. D Immunofluorescence staining was used to detect the expression level of Gli-1 in the cytoplasm and nucleus of Huh7 and HepG2 cells overexpressing ELYS. E qRT-PCR was performed to measure the mRNA levels of canonical Gli-1 target genes (PTCH1 and Gli-1) in Huh7 and HepG2 cells with or without ELYS overexpression. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 Fig. 3ELYS promoted cell migration and stem cell-like features in HCC cells. A Wound healing assays were conducted to assess the migratory capacity of Huh7 and HepG2 cells overexpressing ELYS. B Spheroid formation assays were performed to evaluate the spheroid-forming ability of Huh7 and HepG2 cells overexpressing ELYS. C Flow cytometry was used to detect the expression levels of CD90 in Huh7 and HepG2 cells overexpressing ELYS. D WB assays were used to detect the effect of ELYS overexpression on the expression levels of stemness-associated proteins, including SOX2, OCT4, and Nanog in Huh7 and HepG2 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted cell migration and stem cell-like features in HCC cells. A Wound healing assays were conducted to assess the migratory capacity of Huh7 and HepG2 cells overexpressing ELYS. B Spheroid formation assays were performed to evaluate the spheroid-forming ability of Huh7 and HepG2 cells overexpressing ELYS. C Flow cytometry was used to detect the expression levels of CD90 in Huh7 and HepG2 cells overexpressing ELYS. D WB assays were used to detect the effect of ELYS overexpression on the expression levels of stemness-associated proteins, including SOX2, OCT4, and Nanog in Huh7 and HepG2 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 The activation of Hh signaling in promoting cellular stemness has been observed in various cancers [25], including glioblastoma [26], breast cancer [27], colon cancer [28], and pancreatic cancer [29]. Thus, we subsequently investigated the impact of ELYS on stem cell-like features in HCC cells. The spheroid formation assays demonstrated that overexpression of ELYS significantly enhanced the ability of HCC cells to form spheroids (Fig. 3B). Flow cytometry analysis revealed a significant upregulation in the expression level of CD90 (a stem cell marker) following ELYS overexpression (Fig. 3C). CD90 is closely linked to tumor cell stemness, invasiveness, and resistance to treatment [30]. Furthermore, overexpression of ELYS markedly increased the expression levels of stemness-associated proteins, including SOX2 (SRY-box containing gene 2), OCT4 (Octamer-binding Transcription Factor 4), and Nanog (NANOG Homeobox Protein), suggesting that ELYS promoted cell stemness in HCC cells (Fig. 3D). These stem cell transcription factors play significant roles in promoting the proliferation of tumor cells, maintaining stem cell properties, and enhancing tumor invasiveness and drug resistance [31]. In summary, these findings suggested that ELYS might promote the stem cell-like features of HCC cells by activating the PI3K/AKT and Hh signaling pathways. ELYS promoted the malignant phenotypes and cell stemness in HCC cells by activating the Hh signaling pathway To further validate the hypothesis, GANT-61 [32], a Hh signaling antagonist, was used in Huh7 cells overexpressing ELYS to explore the mechanism by which ELYS targets the Hh signaling pathway in HCC. Our data indicated that GANT-61 normalized the elevated Gli-1 levels in the nucleus induced by the overexpression of ELYS, reversing the effects of ELYS (Fig. 4A). The results of IF assays further validated the phenomenon (Fig. 4B). Furthermore, the results from wound healing and transwell assays indicated that GANT-61 treatment partially restored the migratory and invasive abilities of Huh7 cells enhanced by overexpression of ELYS (Figs. 4C and 5A). The colony formation and MTT assays demonstrated that overexpression of ELYS promoted cell proliferation, while GANT-61 effectively inhibited this proliferative effect (Fig. 5B & C). Importantly, spheroid formation assays showed that overexpression of ELYS enhanced the spheroid formation ability of Huh7 cells, whereas GANT-61 treatment reversed this promotional effect of ELYS on cell stemness (Fig. 5D). Flow cytometry analysis revealed that GANT-61 reversed the upregulation of the stemness marker CD90 induced by overexpression of ELYS (Fig. 5E). Additionally, overexpression of ELYS significantly increased the expression levels of stemness-associated proteins (SOX2, Nanog, and OCT4), whereas GANT-61 attenuated this upregulation (Fig. 5F). These findings highlighted that ELYS promoted the malignant phenotypes and stem cell-like features in HCC cells by activating the Hh signaling pathway. Fig. 4The Hh pathway inhibitor GANT-61 reversed the ELYS-induced nuclear translocation of Gli-1 and cell migration in HCC cells. A A nuclear-cytoplasmic separation kit was utilized to investigate the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. B Immunofluorescence staining was used to detect the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. C Wound healing assays were conducted to assess the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the migratory capacity of Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 The Hh pathway inhibitor GANT-61 reversed the ELYS-induced nuclear translocation of Gli-1 and cell migration in HCC cells. A A nuclear-cytoplasmic separation kit was utilized to investigate the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. B Immunofluorescence staining was used to detect the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. C Wound healing assays were conducted to assess the impact of ELYS overexpression and GANT-61 (10 µM) treatment on the migratory capacity of Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 Fig. 5ELYS promoted the malignant phenotypes and cell stemness in HCC cells by activating the Hh signaling pathway. A Transwell assays were used to examine the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the migration and invasion of Huh7 cells. B Colony formation assays were employed to investigate the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the colony formation of Huh7 cells. C MTT assays were used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the proliferation of Huh7 cells. D Spheroid formation assays were performed to evaluate the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the spheroid-forming ability of Huh7 cells. E Flow cytometry was used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of CD90 in Huh7 cells. F WB assays were used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of SOX2, OCT4, and Nanog in Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted the malignant phenotypes and cell stemness in HCC cells by activating the Hh signaling pathway. A Transwell assays were used to examine the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the migration and invasion of Huh7 cells. B Colony formation assays were employed to investigate the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the colony formation of Huh7 cells. C MTT assays were used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the proliferation of Huh7 cells. D Spheroid formation assays were performed to evaluate the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the spheroid-forming ability of Huh7 cells. E Flow cytometry was used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of CD90 in Huh7 cells. F WB assays were used to detect the effect of ELYS overexpression and GANT-61 (10 µM) treatment on the expression levels of SOX2, OCT4, and Nanog in Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted malignant phenotypes and cellular stemness in HCC cells by activating the PI3K/AKT/Hh signaling axis As demonstrated by the KEGG enrichment analysis above, the DEGs were mainly enriched in the PI3K/AKT and Hh signaling pathways (Fig. 1D). The PI3K/AKT pathway can ultimately activate the downstream transcription factor Gli-1, thus facilitating the activation of the Hh signaling pathway [33]. In HCC, the PI3K/AKT signaling pathway played a crucial role in driving tumorigenesis, progression, and metastasis, and was associated with poor prognosis [34]. Therefore, this study employed the AKT inhibitor (MK-2206 2HCl) to investigate the regulatory role of ELYS in the Hh signaling pathway and malignant phenotypes in HCC cells through the PI3K/AKT signaling pathway. The results demonstrated that in Huh7 cells overexpressing ELYS, the expression levels of p-AKT and Gli-1 were significantly increased, while the expression level of the inhibitory protein in the Hh signaling pathway (SUFU) was decreased. These regulatory effects were reversed after treatment with MK-2206 2HCl (Fig. 6A). Nuclear-cytoplasmic separation experiments demonstrated that MK-2206 2HCl treatment could reverse the ELYS-induced increase in Gli-1 expression within the nucleus (Fig. 6B). This result was also verified by IF assays (Fig. 6C). Thus, these findings indicated that ELYS facilitated the nuclear translocation of Gli-1 by activating the PI3K/AKT signaling pathway, thereby enhancing the activity of the Hh signaling pathway in HCC cells. Fig. 6The PI3K/AKT pathway inhibitor MK-2206 2HCl reversed the ELYS-induced nuclear translocation of Gli-1 and cell migration in HCC cells. A WB assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of PI3K/AKT and Hh pathways-related proteins, including p-AKT, AKT, SUFU, and Gli-1 in Huh7 cells. B A nuclear-cytoplasmic separation kit was utilized to investigate the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. C Immunofluorescence staining was used to detect the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. D Wound healing assays were conducted to assess the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the migratory capacity of Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 The PI3K/AKT pathway inhibitor MK-2206 2HCl reversed the ELYS-induced nuclear translocation of Gli-1 and cell migration in HCC cells. A WB assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of PI3K/AKT and Hh pathways-related proteins, including p-AKT, AKT, SUFU, and Gli-1 in Huh7 cells. B A nuclear-cytoplasmic separation kit was utilized to investigate the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. C Immunofluorescence staining was used to detect the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of Gli-1 protein in both the cytosol and nucleus of Huh7 cells. D Wound healing assays were conducted to assess the impact of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the migratory capacity of Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 In terms of assessing cellular migration and invasion potential, the wound healing assays demonstrated that Huh7 cells overexpressing ELYS exhibited significantly enhanced migratory capacity. However, this enhanced migration was notably inhibited after treatment with MK-2206 2HCl (Fig. 6D). Furthermore, the results of transwell, colony formation, and MTT assays further confirmed that MK-2206 2HCl could reverse the promotive effects of ELYS on cell invasion, migration, colony formation, and proliferation (Fig. 7A, B & C). Importantly, the stem cell-like properties promoted by ELYS, including the promotion of spheroid formation, upregulation of the expression levels of the stemness marker CD90 and the stemness-associated proteins (SOX2, Nanog, and OCT4), were partially inhibited by MK-2206 2HCl treatment (Figs. 7D, E&F). In conclusion, these findings suggested that ELYS promoted the Hh signaling pathway by activating the PI3K/AKT signaling pathway, thereby enhancing the malignant phenotypes and cellular stemness in HCC cells. Fig. 7ELYS enhanced the malignant phenotypes and cell stemness of HCC cells by activating the PI3K/AKT/Hh signaling axis. A Transwell assays were used to examine the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the migration and invasion of Huh7 cells. B Colony formation assays were employed to investigate the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the colony formation of Huh7 cells. C MTT assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the proliferation of Huh7 cells. D Spheroid formation assays were performed to evaluate the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the spheroid-forming ability of Huh7 cells. E Flow cytometry was used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of CD90 in Huh7 cells. F WB assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of SOX2, Nanog, and OCT4 in Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS enhanced the malignant phenotypes and cell stemness of HCC cells by activating the PI3K/AKT/Hh signaling axis. A Transwell assays were used to examine the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the migration and invasion of Huh7 cells. B Colony formation assays were employed to investigate the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the colony formation of Huh7 cells. C MTT assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the proliferation of Huh7 cells. D Spheroid formation assays were performed to evaluate the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the spheroid-forming ability of Huh7 cells. E Flow cytometry was used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of CD90 in Huh7 cells. F WB assays were used to detect the effect of ELYS overexpression and MK-2206 2HCl (25 µM) treatment on the expression levels of SOX2, Nanog, and OCT4 in Huh7 cells. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS-activated PI3K/AKT signaling promoted HCC stemness via the FOXO6/NUP205 axis To further elucidate the molecular mechanism by which the ELYS/PI3K/AKT/Hh axis regulates HCC stemness, bioinformatics analysis using TCGA-HCC datasets was performed. Tumor samples were divided into ELYS-high and ELYS-low groups based on the median expression of ELYS. Differential expression analysis identified 3791 DEGs, with 1902 upregulated and 1889 downregulated in the ELYS-high group compared to the ELYS-low group (Fig. 8A). Notably, among the NUP family genes (which are known to interact with ELYS in nuclear transport and tumor signaling [35, 36]), NUP205 was significantly upregulated in the ELYS-high group. Intersection analysis of transcription factors putatively targeting the NUP205 promoter, genes associated with the PI3K/AKT signaling pathway, and ELYS-high upregulated DEGs further identified two key factors: FOXO6 (Forkhead Box O6) and PITX2 (Paired Like Homeodomain 2) (Fig. 8B). Given that elevated stemness is a hallmark of aggressive HCC, the correlation of these candidates with a stemness signature was evaluated. Both FOXO6-high and PITX2-high tumors had significantly higher stemness scores than low-expression groups (Fig. 8C & D), suggesting their role in stemness regulation. Considering its emerging prominence as a pivotal regulator in tumor progression and a promising therapeutic target [37], FOXO6 was chosen for further experimental validation. Fig. 8Bioinformatic analysis identified FOXO6 and NUP205 as key regulators linking ELYS to stemness in HCC. HCC tumor samples from the TCGA database were dichotomized into ELYS-high and ELYS-low groups based on the median expression level of ELYS. A Volcano plot showed DEGs between ELYS-high and ELYS-low tumor groups. B Venn diagram illustrated the intersection of three gene sets: Transcription factors putatively targeting the NUP205 promoter, genes involved in the PI3K/AKT signaling pathway, and DEGs upregulated in ELYS-high tumors. C Violin plot compared stemness scores, calculated via ssGSEA, between FOXO6-high and FOXO6-low expressing tumors. D Violin plot compared stemness scores between PITX2-high and PITX2-low expressing tumors Bioinformatic analysis identified FOXO6 and NUP205 as key regulators linking ELYS to stemness in HCC. HCC tumor samples from the TCGA database were dichotomized into ELYS-high and ELYS-low groups based on the median expression level of ELYS. A Volcano plot showed DEGs between ELYS-high and ELYS-low tumor groups. B Venn diagram illustrated the intersection of three gene sets: Transcription factors putatively targeting the NUP205 promoter, genes involved in the PI3K/AKT signaling pathway, and DEGs upregulated in ELYS-high tumors. C Violin plot compared stemness scores, calculated via ssGSEA, between FOXO6-high and FOXO6-low expressing tumors. D Violin plot compared stemness scores between PITX2-high and PITX2-low expressing tumors Then, the ELYS-FOXO6-NUP205 axis was validated via in vitro experiments. A significant increase in FOXO6 protein levels was confirmed in Huh7 cells following ELYS overexpression (Fig. 9A). Bioinformatic prediction suggested the presence of putative FOXO6 binding sites in the NUP205 promoter region (Fig. 9B). A dual-luciferase reporter assay showed that ELYS overexpression significantly enhanced the activity of the wild-type promoter, whereas this enhancing effect was abolished upon mutation of the predicted FOXO6 binding site, with the mutant promoter activity showing no significant change (Fig. 9C). The physical binding of FOXO6 to this specific promoter region was further confirmed by ChIP assay, wherein chromatin fragments immunoprecipitated with an anti-FOXO6 antibody showed significant enrichment of the NUP205 promoter sequence in ELYS-overexpressing group compared to the control group, as detected by qRT-PCR (Fig. 9D). To explore FOXO6’s function, three siRNA sequences (siR-FOXO6-1/2/3) were designed to knock down FOXO6 in Huh7 cells. WB assay confirmed the transfection efficiency, with siR-FOXO6-3 showing the most significant knockdown effect and thus selected for subsequent experiments (Fig. 9E). FOXO6 knockdown resulted in a marked decrease in NUP205 protein expression that was promoted by ELYS overexpression and, crucially, abolished the ELYS-induced nuclear accumulation of Gli-1 (Fig. 9F). Furthermore, the expression of key stemness factors (SOX2, Nanog, OCT4) promoted by ELYS was significantly suppressed upon FOXO6 knockdown (Fig. 9G). To further determine whether the expression of FOXO6 and NUP205 is dependent on PI3K/AKT signaling, ELYS-overexpressing Huh7 cells were treated with the AKT inhibitor MK-2206 2HCl. As shown in Fig. 9H, MK-2206 2HCl treatment significantly reduced the ELYS-induced upregulation of FOXO6 and NUP205, indicating that the expression of both molecules is regulated by PI3K/AKT activity. Collectively, these findings establish that ELYS activates the PI3K/AKT pathway, which in turn upregulates FOXO6. FOXO6 then directly binds to and activates the transcription of NUP205, leading to Gli-1 nuclear translocation and activation of Hh signaling. This PI3K/AKT/FOXO6/NUP205 axis is essential for ELYS to mediate the stemness properties of HCC cells. Fig. 9ELYS promoted HCC stemness by activating FOXO6-dependent transcription of NUP205. A The protein expression of FOXO6 was detected by WB assays in ELYS-overexpressing Huh7 cells. B FOXO6 has putative binding sites in the promoter region of NUP205. C The potential binding site of FOXO6 to the NUP205 promoter was mutated, and dual-luciferase reporter assays were used to detect the luciferase intensity of the wild-type or mutant sequence in ELYS-overexpressing Huh7 cells. D The binding relationship between FOXO6 and the NUP205 promoter was verified by ChIP assay. E FOXO6 was knocked down in Huh7 cells, and the transfection efficiency was determined by WB assays. F The protein expression of NUP205 in Huh7 cells and the expression of Gli-1 in Huh7 cell nucleus were detected by WB assays. G WB assays were used to detect the expression levels of SOX2, Nanog, and OCT4 in Huh7 cells. H ELYS-overexpressing Huh7 cells were treated with or without the AKT inhibitor MK-2206 2HCl, and the protein expression levels of FOXO6 and NUP205 were detected by WB assays. β-actin served as the loading control. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted HCC stemness by activating FOXO6-dependent transcription of NUP205. A The protein expression of FOXO6 was detected by WB assays in ELYS-overexpressing Huh7 cells. B FOXO6 has putative binding sites in the promoter region of NUP205. C The potential binding site of FOXO6 to the NUP205 promoter was mutated, and dual-luciferase reporter assays were used to detect the luciferase intensity of the wild-type or mutant sequence in ELYS-overexpressing Huh7 cells. D The binding relationship between FOXO6 and the NUP205 promoter was verified by ChIP assay. E FOXO6 was knocked down in Huh7 cells, and the transfection efficiency was determined by WB assays. F The protein expression of NUP205 in Huh7 cells and the expression of Gli-1 in Huh7 cell nucleus were detected by WB assays. G WB assays were used to detect the expression levels of SOX2, Nanog, and OCT4 in Huh7 cells. H ELYS-overexpressing Huh7 cells were treated with or without the AKT inhibitor MK-2206 2HCl, and the protein expression levels of FOXO6 and NUP205 were detected by WB assays. β-actin served as the loading control. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted tumor growth and lung metastasis of HCC by activating the PI3K/AKT/Hh signaling axis in vivo To validate the effect of ELYS mediated through the PI3K/AKT/Hh signaling axis in vivo, xenograft tumor models were established using Huh7 cells transfected with Lenti-ELYS or control. The stable ELYS overexpression efficiency was confirmed by WB assays (Fig. 10A). Consistent with the results obtained from cell experiments conducted in vitro, overexpression of ELYS promoted tumor growth in vivo. However, treatment with the AKT inhibitor (MK-2206 2HCl) efficiently attenuated the tumor-promoting effects of ELYS (Fig. 10B, C & D). The results demonstrated that MK-2206 2HCl treatment significantly inhibited the tumor cell proliferation induced by ELYS (Fig. 10E & F). Furthermore, IHC analysis of relevant indicators in tumor samples demonstrated that overexpression of ELYS results in a decrease in the expression level of SUFU, and an increase in the expression levels of Ki67 (a tumor cell proliferation marker) [38], p-AKT, and Gli-1. Conversely, treatment with MK-2206 2HCl reversed the regulatory effects of ELYS on these markers in HCC (Fig. 10F). These findings were consistent with the results that MK-2206 2HCl was able to partially counteract the impact of ELYS on cell proliferation and PI3K/AKT/ Hh signaling axis in HCC cells. Fig. 10ELYS promoted tumor growth of HCC by activating the PI3K/AKT/Hh signaling axis in vivo. The mice were subcutaneously injected with Huh7 cells stably transfected with ELYS-overexpressing plasmids or the pcDNA3.1 plasmids (4 × 106/200 µL) (n = 6). Treatment group mice were orally gavaged with 100 µL of MK-2206 2HCl (120 mg/kg), while mice in the other two groups were given equal amounts of saline. A WB assays were used to verify the transfection efficiency. B–D Once the tumors reached a volume of 1500 mm³, all mice were euthanized. (B) Tumor tissues were isolated from the mice and then (C) the volume and (D) weight of the tumors were recorded. (E) HE staining was used to examine the effects of ELYS overexpression and MK-2206 2HCl treatment on tumor tissues. (F) IHC was used to detect the expression levels of Ki67, ELYS, p-AKT, SUFU, and Gli-1 in tumor tissues. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted tumor growth of HCC by activating the PI3K/AKT/Hh signaling axis in vivo. The mice were subcutaneously injected with Huh7 cells stably transfected with ELYS-overexpressing plasmids or the pcDNA3.1 plasmids (4 × 106/200 µL) (n = 6). Treatment group mice were orally gavaged with 100 µL of MK-2206 2HCl (120 mg/kg), while mice in the other two groups were given equal amounts of saline. A WB assays were used to verify the transfection efficiency. B–D Once the tumors reached a volume of 1500 mm³, all mice were euthanized. (B) Tumor tissues were isolated from the mice and then (C) the volume and (D) weight of the tumors were recorded. (E) HE staining was used to examine the effects of ELYS overexpression and MK-2206 2HCl treatment on tumor tissues. (F) IHC was used to detect the expression levels of Ki67, ELYS, p-AKT, SUFU, and Gli-1 in tumor tissues. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 To investigate the effects of ELYS on lung metastasis, Huh7 cells stably overexpressing ELYS were inoculated into nude mice via the tail vein. After a two-week observation period, the nude mice were euthanized, and their lung tissues were harvested for photography to document the number of metastatic foci. The experimental results revealed that ELYS significantly promoted HCC-associated lung metastasis and lung injury. However, these promoting effects were effectively reversed following treatment with MK-2206 2HCl (Fig. 11A & B). Fig. 11ELYS promoted lung metastasis of HCC in vivo. Nude mice were inoculated with Huh7 cells stably transfected with ELYS-overexpressing plasmids or with the pcDNA3.1 plasmids via tail vein injection (4 × 106/200 µL). Treatment group mice were orally gavaged with 100 µL of MK-2206 2HCl (120 mg/kg), while mice in the other two groups were given equal amounts of saline. Three weeks later, the nude mice were euthanized. A Lung tissues were isolated from the mice, and the number of metastatic foci was recorded. B HE staining was used to observe the effect of ELYS overexpression and MK-2206 2HCl treatment on lung tissues. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 ELYS promoted lung metastasis of HCC in vivo. Nude mice were inoculated with Huh7 cells stably transfected with ELYS-overexpressing plasmids or with the pcDNA3.1 plasmids via tail vein injection (4 × 106/200 µL). Treatment group mice were orally gavaged with 100 µL of MK-2206 2HCl (120 mg/kg), while mice in the other two groups were given equal amounts of saline. Three weeks later, the nude mice were euthanized. A Lung tissues were isolated from the mice, and the number of metastatic foci was recorded. B HE staining was used to observe the effect of ELYS overexpression and MK-2206 2HCl treatment on lung tissues. Three independent experiments were performed for the assays. The statistical significance level was set at 0.05, with * corresponding to a p-value < 0.05 and ** corresponding to a p-value < 0.01 In summary, our findings demonstrated that ELYS facilitated lung metastasis and lung injury of HCC, a process that could be reversed by MK-2206 2HCl treatment. These findings emphasized that ELYS promoted the Hh signaling pathway by activating the PI3K/AKT cascade, ultimately facilitating tumor growth and metastasis in HCC. High expression of ELYS, FOXO6, and NUP205 was associated with tumor progression and worse overall survival in patients with hepatocellular carcinoma To evaluate the clinical relevance of the ELYS/FOXO6/NUP205 axis, the expression patterns and prognostic value of these genes were analyzed using human HCC bulk RNA-seq data and clinical samples. Immunohistochemistry was performed on clinical HCC tissue samples, which were divided into ELYS high- and low-expression groups. The results showed that FOXO6 and NUP205 expression levels were positively correlated with ELYS expression, with higher FOXO6 and NUP205 signals observed in the ELYS high-expression group compared to the low-expression group (Fig. 12A). Subsequently, transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) were utilized for further analyses. Differential expression analysis between tumor (n = 365) and adjacent normal (n = 50) tissues identified 8551 differentially expressed genes, as visualized in a volcano plot (Fig. 12B). Among these, 5940 genes were upregulated and 2611 genes were downregulated in the tumor group (Fig. 12C). A heatmap further displayed the expression patterns of these differentially expressed genes across all 415 samples, showing clear segregation between tumor and normal tissues (Fig. 12D). Violin-boxplots revealed that ELYS, FOXO6 and NUP205 were all significantly overexpressed in HCC samples compared with adjacent normal tissues (Fig. 12E). Kaplan-Meier survival analysis demonstrated that patients with low expression of ELYS (p = 0.038), FOXO6 (p = 0.0437) and NUP205 (p = 0.000358) had significantly better overall survival than those with high expression, indicating that high expression of these genes is associated with poor prognosis (Fig. 12F). Clinical correlation analysis between high- and low-expression groups of ELYS, FOXO6 and NUP205 was then performed (Table 4). As summarized in Table 4, the ELYS high-expression group was comparable to the low-expression group in age, sex, N stage and M stage (all P > 0.05). Although overall Stage did not reach statistical significance (P = 0.183), the ELYS high-expression group exhibited a higher proportion of Stage III/IV patients (33.9% vs. 25.0%) and T3/4 patients (32.3% vs. 24.1%). For FOXO6, high expression was significantly associated with advanced overall Stage (36.3% vs. 22.2%, P = 0.028) and higher T stage (P = 0.009), with an increased proportion of T3/4 patients (34.7% vs. 21.3%). For NUP205, high expression was also significantly correlated with advanced overall Stage (37.0% vs. 21.0%, P = 0.012) and T stage (P = 0.029), including a markedly higher proportion of T3/4 patients (35.4% vs. 20.0%). Collectively, these findings demonstrate that ELYS, FOXO6 and NUP205 are significantly overexpressed in HCC, and their high expression is associated with advanced clinicopathological features and worse overall survival, supporting their pro-tumorigenic roles in HCC progression. Table 4Association of ELYS, FOXO6, and NUP205 expression with clinicopathological characteristics in HCC patientsClinicopathological characteristics of HCC patients stratified by ELYS expressionCharacterLevelHigh expression of ELYS (n = 124)Low expression of ELYS (n = 108) P Age (%)<=6072 (58.1)55 (50.9)0.338> 6052 (41.9)53 (49.1)Gender (%)Female41 (33.1)32 (29.6)0.674Male83 (66.9)76 (70.4)Stage (%)Stage I/II82 (66.1)81 (75.0)0.183Stage III/IV42 (33.9)27 (25.0)T_Stage (%)T156 (45.2)59 (54.6)0.294T228 (22.6)23 (21.3)T3/440 (32.3)26 (24.1)N_Stage (%)N0121 (97.6)107 (99.1)0.714N13 (2.4)1 (0.9)M_Stage (%)M0123 (99.2)106 (98.1)0.904M11 (0.8)2 (1.9)Clinicopathological characteristics of HCC patients stratified by FOXO6 expressionCharacterLevelHigh expression of FOXO6 (n = 124)Low expression of FOXO6 (n = 108) P Age (%)<=6082 (66.1)45 (41.7)<0.001> 6042 (33.9)63 (58.3)Gender (%)Female48 (38.7)25 (23.1)0.016Male76 (61.3)83 ( 76.9)Stage (%)Stage I/II79 (63.7)84 (77.8)0.028Stage III/IV45 (36.3)24 (22.2)T_Stage (%)T150 (40.3)65 (60.2)0.009T231 (25.0)20 (18.5)T3/443 (34.7)23 (21.3)N_Stage (%)N0121 (97.6)107 (99.1)0.714N13 (2.4)1 (0.9)M_Stage (%)M0121 (97.6)108 (100.0)0.296M13 (2.4)0 (0.0)Clinicopathological characteristics of HCC patients stratified by NUP205 expressionCharacterLevelHigh expression of NUP205 (n = 127)Low expression of NUP205 (n = 105) P Age (%)<=6076 (59.8)51 (48.6)0.113> 6051 (40.2)54 (51.4)Gender (%)Female48 (37.8)25 (23.8)0.032Male79 (62.2)80 (76.2)Stage (%)Stage I/II80 (63.0)83 (79.0)0.012Stage III/IV47 (37.0)22 (21.0)T_Stage (%)T155 (43.3)60 (57.1)0.029T227 (21.3)24 (22.9)T3/445 (35.4)21 (20.0)N_Stage (%)N0124 (97.6)104 (99.0)0.753N13 ( 2.4)1 ( 1.0)M_Stage (%)M0126 (99.2)103 (98.1)0.868M11 ( 0.8)2 ( 1.9) Table 4Association of ELYS, FOXO6, and NUP205 expression with clinicopathological characteristics in HCC patientsClinicopathological characteristics of HCC patients stratified by ELYS expressionCharacterLevelHigh expression of ELYS (n = 124)Low expression of ELYS (n = 108) P Age (%)<=6072 (58.1)55 (50.9)0.338> 6052 (41.9)53 (49.1)Gender (%)Female41 (33.1)32 (29.6)0.674Male83 (66.9)76 (70.4)Stage (%)Stage I/II82 (66.1)81 (75.0)0.183Stage III/IV42 (33.9)27 (25.0)T_Stage (%)T156 (45.2)59 (54.6)0.294T228 (22.6)23 (21.3)T3/440 (32.3)26 (24.1)N_Stage (%)N0121 (97.6)107 (99.1)0.714N13 (2.4)1 (0.9)M_Stage (%)M0123 (99.2)106 (98.1)0.904M11 (0.8)2 (1.9)Clinicopathological characteristics of HCC patients stratified by FOXO6 expressionCharacterLevelHigh expression of FOXO6 (n = 124)Low expression of FOXO6 (n = 108) P Age (%)<=6082 (66.1)45 (41.7)<0.001> 6042 (33.9)63 (58.3)Gender (%)Female48 (38.7)25 (23.1)0.016Male76 (61.3)83 ( 76.9)Stage (%)Stage I/II79 (63.7)84 (77.8)0.028Stage III/IV45 (36.3)24 (22.2)T_Stage (%)T150 (40.3)65 (60.2)0.009T231 (25.0)20 (18.5)T3/443 (34.7)23 (21.3)N_Stage (%)N0121 (97.6)107 (99.1)0.714N13 (2.4)1 (0.9)M_Stage (%)M0121 (97.6)108 (100.0)0.296M13 (2.4)0 (0.0)Clinicopathological characteristics of HCC patients stratified by NUP205 expressionCharacterLevelHigh expression of NUP205 (n = 127)Low expression of NUP205 (n = 105) P Age (%)<=6076 (59.8)51 (48.6)0.113> 6051 (40.2)54 (51.4)Gender (%)Female48 (37.8)25 (23.8)0.032Male79 (62.2)80 (76.2)Stage (%)Stage I/II80 (63.0)83 (79.0)0.012Stage III/IV47 (37.0)22 (21.0)T_Stage (%)T155 (43.3)60 (57.1)0.029T227 (21.3)24 (22.9)T3/445 (35.4)21 (20.0)N_Stage (%)N0124 (97.6)104 (99.0)0.753N13 ( 2.4)1 ( 1.0)M_Stage (%)M0126 (99.2)103 (98.1)0.868M11 ( 0.8)2 ( 1.9) Association of ELYS, FOXO6, and NUP205 expression with clinicopathological characteristics in HCC patients Fig. 12High expression of ELYS, FOXO6, and NUP205 was associated with tumor progression and worse overall survival in patients with hepatocellular carcinoma. A Immunohistochemistry was performed to detect the expression levels of ELYS, FOXO6, and NUP205 in clinical HCC tissue samples. B Differential expression analysis of human bulk RNA-seq data between HCC and adjacent normal tissues was shown, including a volcano plot of differentially expressed genes (Tumor, n = 365; Normal, n = 50). C The numbers of up-regulated (orange), down-regulated (purple), and non-significant (gray) differentially expressed genes were presented in a bar plot. D A heatmap displayed the differentially expressed genes across 415 samples, with rows annotated to indicate up-regulated (yellow) or down-regulated (purple) genes. E Violin-boxplots illustrated the log₂(FPKM + 1)-transformed expression levels of ELYS, FOXO6, and NUP205 in tumor versus normal tissues, and significance was indicated by asterisks. F Kaplan-Meier survival curves for high- (yellow) and low-expression (purple) groups of ELYS, FOXO6, and NUP205 were shown, with p-values from log-rank tests comparing overall survival High expression of ELYS, FOXO6, and NUP205 was associated with tumor progression and worse overall survival in patients with hepatocellular carcinoma. A Immunohistochemistry was performed to detect the expression levels of ELYS, FOXO6, and NUP205 in clinical HCC tissue samples. B Differential expression analysis of human bulk RNA-seq data between HCC and adjacent normal tissues was shown, including a volcano plot of differentially expressed genes (Tumor, n = 365; Normal, n = 50). C The numbers of up-regulated (orange), down-regulated (purple), and non-significant (gray) differentially expressed genes were presented in a bar plot. D A heatmap displayed the differentially expressed genes across 415 samples, with rows annotated to indicate up-regulated (yellow) or down-regulated (purple) genes. E Violin-boxplots illustrated the log₂(FPKM + 1)-transformed expression levels of ELYS, FOXO6, and NUP205 in tumor versus normal tissues, and significance was indicated by asterisks. F Kaplan-Meier survival curves for high- (yellow) and low-expression (purple) groups of ELYS, FOXO6, and NUP205 were shown, with p-values from log-rank tests comparing overall survival Discussion HCC stood as one of the leading causes of cancer-related mortality globally, with distant metastasis, particularly lung metastasis, accounting for approximately 47% of HCC-related mortality cases and serving as a crucial factor contributing to patient mortality [39, 40]. Despite advancements made in HCC treatment modalities, including liver transplantation, surgical resection, and targeted therapy, the challenges associated with early diagnosis and the high metastatic rate of advanced tumors continued to limit therapeutic efficacy, resulting in poor patient prognosis [41]. This poor outcome is largely driven by complex molecular networks, where oncogenes like PAIP1 [42] and intricate regulatory axes, such as the LINC00346/β-catenin/MYC positive feedback loop [43], critically promote HCC development. Furthermore, non-coding RNAs have emerged as pivotal regulators, exemplified by FGD5-AS1, which facilitates tumor progression by sponging miR-873-5p to upregulate GTPBP4 [44], and NEAT1_2 which contributes to radioresistance via the miR-101-3p/WEE1 axis [45]. In this context, the findings of this study underscore the pivotal role of ELYS and associated signaling pathways in the malignant progression of HCC, highlighting their potential as targets for developing novel therapeutic strategies. In recent years, ELYS, a multifunctional nucleoporin, has garnered increasing attention for its role in cancer. Studies have demonstrated that ELYS plays crucial roles in cell proliferation, survival, and the assembly of nuclear pore complexes [16, 46]. As a key nucleoporin, ELYS is instrumental in the transport of MYC genes regulated by the WNT signaling pathway, thereby influencing the initiation and progression of colorectal cancer [19]. In a zebrafish model of HCC, mutations in ELYS were observed to exacerbate oncogenic stress responses and limit excessive liver growth [19]. To evaluate the impact of ELYS in HCC, the DEGs were identified in control and ELYS-overexpressing Huh7 cells through a transcriptome sequencing analysis. The results showed that DEGs associated with ELYS were mainly enriched in the Hh and PI3K/AKT pathways, highlighting the potential role of ELYS in these oncogenic signaling pathways. Further functional studies confirmed that overexpression of ELYS upregulated key proteins in the Hh and PI3K/AKT pathways, including Gli-1, p-AKT, and downstream effector proteins while decreasing the expression of inhibitory molecule (SUFU). Gli-1, as a key transcription factor in the Hh signaling pathway, is involved in regulating the proliferation, migration, and invasion of HCC cells [14]. Overexpression of ELYS promoted the nuclear translocation of Gli-1, indicating that ELYS may contribute to the malignant phenotypes of HCC cells by enhancing the transcriptional activity of Gli-1. The Hh and PI3K/AKT pathways played vital roles in the development of HCC. The abnormal activation of the Hh pathway was positively correlated with poor prognosis, promoting tumor proliferation, survival, self-renewal, and invasive growth through its key effectors such as Gli-1 [47, 48]. As the core transcription factor of the Hh pathway, Gli-1 directly regulated the expression of downstream genes, thereby mediating the stem-like characteristics, invasive behavior, and chemotherapy resistance of tumor cells [49]. Furthermore, the Hh pathway was proven to be an important pathway for maintaining the stem-like properties of tumor cells, driving their self-renewal and differentiation, and promoting tumor progression in various cancers [50]. On the other hand, the PI3K/AKT pathway further promoted the malignant progression of HCC by regulating cell proliferation, survival, and apoptosis [47]. Studies found that M2 macrophages can regulate cell migration and infiltration by affecting the PI3K/AKT pathway, for example, inhibiting the migration and infiltration of glioma cells [51]. Additionally, the PI3K/AKT pathway induced excessive activation of the Hh pathway by activating effectors such as Gli-1, thereby enhancing the stemness of breast cancer cells [52]. In this study, our results demonstrated that ELYS facilitated the nuclear translocation of Gli-1 by activating the PI3K/AKT signaling pathway, thereby upregulating the Hh signaling pathway. Moreover, ELYS overexpression significantly promoted tumor cell proliferation, migration, invasion, and stemness. In HCC cells overexpressing ELYS, stemness markers such as CD90, SOX2, Nanog, and OCT4 were markedly upregulated, accompanied by an increased spheroid formation capacity (a key indicator of stemness). Inhibition experiments further clarified the interaction between ELYS and the Hh and PI3K/AKT pathways. Treatment with the Hh pathway inhibitor GANT-61 reversed ELYS-induced Gli-1 upregulation and mitigated malignant phenotypes, including enhanced migration, invasion, proliferation, and stemness. Importantly, the AKT inhibitor MK-2206 2HCl suppressed the activity of the Hh signaling pathway by reducing both Gli-1 expression and its nuclear translocation, highlighting the role of ELYS in promoting Hh signaling through the PI3K/AKT signaling pathway. To bridge the gap between the upstream PI3K/AKT signaling and the downstream Hh pathway activation, an integrative bioinformatics analysis was conducted, which identified the nucleoporin NUP205 as a uniquely upregulated gene in ELYS-high HCC tumors and pinpointed the transcription factor FOXO6 as a key candidate linking ELYS to NUP205 and stemness. FOXO6, a paired-like homeodomain transcription factor with distinct isoforms and regulatory mechanisms, has been confirmed to be highly expressed in HCC and associated with tumor progression, stemness features, and chemotherapy resistance, findings consistent with its role as a linker in this study [53, 54]. Experimental validation confirmed that ELYS upregulates FOXO6 protein expression. This regulatory relationship aligns with previous research showing that oncogenic signals can enhance FOXO6 expression and activity in cancer cells, further supporting FOXO6’s oncogenic role in this context [55]. FOXO6, in turn, was shown to directly bind to the NUP205 promoter and activate its transcription, as confirmed by dual-luciferase reporter and ChIP assays. NUP205, as a major structural nucleoporin (NUP), belongs to the nuclear pore complex (NPC), a large channel mediating nucleocytoplasmic transport, composed of ~ 30 NUPs [36]. Notably, ELYS is a core NUP that binds chromatin and connects it to NPCs during mitosis and interphase; its knockdown leads to peripheral chromatin displacement from the nuclear envelope and derepression of genes [56]. Additionally, ELYS integrates into the NPC’s heptameric Y-complex via interactions with Nup120/160 and Nup37, a scaffold NUP, underscoring its essential role in NPC assembly and functionality [35]. The critical functional role of this ELYS/FOXO6/NUP205 axis was underscored by the finding that FOXO6 knockdown abolished the ELYS-induced effects on NUP205 expression, Gli-1 nuclear translocation, and the expression of stemness factors. Given that ELYS is a core component of the nuclear pore complex (NPC) and NUP205 is a major structural nucleoporin, the transcriptional induction of NUP205 by FOXO6 suggests a novel positive feedback loop that may remodel the NPC to facilitate the nuclear import of key oncogenic cargo. This NPC remodeling aligns with reports that NUPs (e.g., Sec13, ELYS) can induce chromatin decondensation via recruitment of chromatin-remodeling complexes (e.g., PBAP) and influence gene expression, further linking NPC function to oncogenic chromatin states [57]. Moreover, NPC function is tightly linked to nuclear lamins, and dysregulation of NUPs/lamins can lead to DNA damage and reduced efficacy of antineoplastic treatments, implying that the ELYS-FOXO6-NUP205 axis may also impact HCC therapy response by altering nuclear transport [58]. In vivo studies further validated the role of ELYS in promoting tumor growth and metastasis. Xenograft models demonstrated that ELYS enhanced tumor proliferation and lung metastasis, accompanied by elevated expression of Ki67, p-AKT, and Gli-1. These tumorigenic effects were reversed after treatment with AKT inhibitors, highlighting the therapeutic potential of targeting the PI3K/AKT/Hh signaling axis induced by ELYS in HCC. Our clinical data further support the pro-tumorigenic relevance of this axis. Analysis of clinical HCC samples and TCGA data revealed that high expression of ELYS, FOXO6, and NUP205 is significantly associated with advanced clinicopathological features (including higher overall stage and T stage) and worse overall survival. These findings align with our functional studies, reinforcing the clinical significance of the ELYS/FOXO6/NUP205 axis as a potential prognostic indicator and therapeutic target in HCC. Despite some progress in the treatment of HCC, considerable challenges persist. Current therapies, including liver transplantation, targeted therapies, and immune checkpoint inhibitors, frequently fail to effectively control tumor metastasis and recurrence, highlighting the necessity for more precise therapeutic targets. In this study, we have demonstrated through both in vitro and in vivo experiments that ELYS promotes cell stemness and malignant phenotypes by activating the PI3K/AKT/Hh signaling axis, thereby enhancing tumor growth and metastasis in HCC. These findings reveal the critical role of ELYS as a potential therapeutic target. However, we acknowledge several limitations in the current study. First, the precise molecular mechanism by which ELYS activates the PI3K/AKT pathway remains to be fully elucidated. To our knowledge, no previous study has reported a direct link between ELYS and PI3K/AKT signaling. ELYS is traditionally known as a nucleoporin involved in nuclear transport and mitotic spindle assembly, and its potential role as a direct regulator of PI3K/AKT signaling has not been previously characterized. Dissecting this mechanism would require extensive additional experiments, such as co-immunoprecipitation coupled with mass spectrometry to identify ELYS-interacting proteins, domain mapping, and mutational analysis. These investigations represent a substantial body of work that is beyond the scope of the current study, and we plan to pursue this important question in our future research. Second, the clinical validation of the ELYS/FOXO6/NUP205 axis was primarily based on TCGA database analysis and a relatively small cohort of our own clinical samples. Future studies with larger, prospectively collected patient cohorts and more complete clinical annotation are warranted to further confirm the clinical significance of this signaling axis. Third, although we have demonstrated that ELYS promotes HCC stemness and malignant phenotypes through the PI3K/AKT/FOXO6/NUP205/Hh axis, whether other downstream effectors or parallel signaling pathways are also involved remains to be investigated. In conclusion, our study establishes ELYS as an upstream activator of the PI3K/AKT pathway and defines the downstream FOXO6/NUP205 axis as essential for transmitting oncogenic signals to the Hh pathway, ultimately driving the stem-like properties that underlie HCC progression and metastasis. This expanded understanding of the molecular circuitry of HCC aggressiveness highlights the potential of targeting components of this axis for therapeutic intervention. Conclusion In conclusion, this study elucidates a novel PI3K/AKT-FOXO6-NUP205 signaling axis that drives HCC progression. It is established that ELYS activates the PI3K/AKT pathway, which in turn upregulates the transcription factor FOXO6. FOXO6 directly binds to and transactivates the NUP205 promoter, and this FOXO6-NUP205 axis is essential for relaying the oncogenic signal to the Hedgehog pathway, ultimately culminating in the enhancement of stemness and metastasis. These findings not only decipher a previously unrecognized signaling circuitry in HCC but also nominate the PI3K/AKT-FOXO6-NUP205 axis as a promising therapeutic target for intervention.